ClinicalTrials.gg
Status unknownNCT04880512Updated Sep 30, 2021

The Safety, Tolerability, and Pharmacokinetics of SYHX1901 Tablets in Chinese Healthy Subjects

A Phase 1 interventional study of SYHX 1901 tablets and Placebo in Healthy Subjects, sponsored by CSPC Ouyi Pharmaceutical Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-30.

Sponsored by CSPC Ouyi Pharmaceutical Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2021), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a phase I clinical trial to evaluate the safety, tolerability and pharmacokinetic characteristics of single ascending doses and multiple ascending doses of SYHX1901 tablets in Chinese healthy subjects

Read the detailed description

This study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetic characteristics of single ascending doses (part 1) and multiple ascending doses (part 2) of SYHX1901 tablets in Chinese healthy subjects.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

CSPC Ouyi Pharmaceutical Co., Ltd. is the lead sponsor of 30 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged 18 to 45 years (inclusive);
  2. Have a (BMI) between 18.0 and 26.0 kg/m2 (inclusive) and weigh at least 45.0 kg (female) or 50.0 kg (male) at screening;
  3. Satisfactory medical assessment with no or relevant abnormalities as determined by medical history, vital signs, physical examination, and clinical laboratory tests (hematology, urinalysis, and coagulation);
  4. Subjects and their partners agree to use effective n4. Subjects and their partners agree to use effective non-hormonal measures (e.g., condoms, inert intrauterine devices, female barriers (cervix cap or diaphragm with spermicide), vaginal contraceptive ring, etc.) from signing the form to 6 months after the end of the study, or have taken permanent contraceptive measures (e.g., bilateral fallopian tube ligation, vasectomy, etc.); male subjects have no sperm donation plan from signing the informed consent to 6 months after the end of the study, female subjects have no egg donation plan from signing the informed consent form to 6 months after the end of the study;
  5. Subjects who fully understand the study, voluntarily participate in the trial and sign the informed consent form.

Exclusion criteria

Exclusion Criteria:

  1. Prior neurological/ psychiatric, respiratory system, endocrine system, blood system, skeletal-muscular system diseases or liver and kidney dysfunction or other diseases that may affect the results of the study;
  2. History of severe allergies, herpes zoster infection, or tuberculosis;
  3. Those who have taken any prescription drugs, over-the-counter drugs, proprietary Chinese medicines, herbal medicines, vitamin dietary supplements and health products within 4 weeks before signing the , and those who use oral long-acting or use embedded long-acting contraceptives;
  4. Subjects with diseases affecting drug absorption, distribution, metabolism and excretion as judged by investigator (e.g., acute and chronic diarrhea, acute and chronic gastritis, etc.);
  5. Surgery history within 6 months prior to signing the informed consent;
  6. Subjects with surgery plan (including cosmetic surgery, dental surgery and oral surgery), or strenuous exercise plan (including physical contact sports or collision sports) during the trial period;
  7. Subjects with any abnormalities in , interval greater than 450 ms (male) or 470 ms (female), or with a history of prolonged QTcF interval;
  8. Subjects with one or more abnormalities in the vital signs at screening: ear temperature >37.5ºC, pulse rate >100 beats/min, systolic blood pressure ≥140 mmHg or \<90 mmHg, diastolic blood pressure >90 mmHg or \<50 mmHg;
  9. The white blood cell count, the absolute value of neutrophils and the absolute value of lymphocytes are below the lower limit or higher than the upper limit of the reference value, and the percentage of reticulocyte (RET) is below the lower limit of the reference value in routine blood tests at screening;
  10. History of acute respiratory or systemic infections within 2 weeks before signing the informed consent;
  11. Blood lost or donation more than 400 mL within 3 months before signing the informed consent;
  12. Alcohol abuse: consumption of more than 14 units of alcohol per week within 4 weeks prior to signing the informed consent or positive test for Alcohol at screening;
  13. Smoker: more than 5 cigarettes per day within 6 months prior to signing informed consent;
  14. Habitual intake of excessive xanthine- or caffeine-containing food, beverages, or other factors, which may interfere the absorption, distribution, metabolism, or excretion of drugs, within 4 weeks prior to screening;
  15. Subjects have participated in clinical trials of any drug or medical device within 3 months before signing the informed consent;
  16. History of substance abuse within the 1 years prior to signing the informed consent, or positive test for drug abuse at screening;
  17. Female subjects who are pregnant or lactating;
  18. Anti-Mullerian hormone (female only) test results not within the reference range at screening;
  19. Positive test for surface antigen (HBsAg), antibody (anti-HCV), antibody (anti-HIV) or Treponema Pallidum antibody (Anti-TP) at screening;
  20. Suspected or known allergy to the test drug or any ingredient in the test drug, or subjects with allergic constitution;
  21. Not suitable for this trial as determined by the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
102 participants (estimated)

Study arms

  • Experimental
    SYHX 1901 tablets for SAD

    Two subjects will be enrolled in a single dose group which is recommended as the initial dose. 8 out of 10 healthy subjects will be randomized to receive a single dose of SYHX 1901 tablets in fasted state.

    Drug: SYHX 1901 tablets

  • Placebo comparator
    Placebo for SAD

    2 out of 10 healthy subjects will be randomized to receive a single dose of placebo in fasted state

    Drug: Placebo

  • Experimental
    SYHX 1901 tablets for MAD

    8 out of 10 healthy subjects will be randomized to receive multiple doses of SYHX 1901 tablets in fasted state

    Drug: SYHX 1901 tablets

  • Placebo comparator
    Placebo for MAD

    2 out of 10 healthy subjects will be randomized to receive multiple doses of placebo in fasted state

    Drug: Placebo

Interventions

  • SYHX 1901, oral tablets, in fasted state

  • DrugPlacebo

    Matching placebo, oral tablets, in fasted state

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of SYHX1901 tablets

    The safety and tolerability of single or multiple doses of SYHX1901 tablets administered orally will be assessed by incidence and severity of adverse events (AEs), abnormalities in clinical laboratory assessments, ECGs, vital sign assessments, and physical exams.

    Time frame: SAD: up to14 days after the dosing, MAD: up to 7 days after the last dosing

Secondary outcomes

  1. The PK of SYHX1901 following single-dose and multiple doses

    Peak Plasma Concentration (Cmax) of SYHX1901 following single-dose and multiple doses

    Time frame: Pre-dose and multiple timepoints up to 144 hours after the last dose

  2. The PK of SYHX1901 following single-dose and multiple doses

    Area under the plasma concentration versus time curve (AUC) of SYHX1901 following single-dose and multiple doses

    Time frame: Pre-dose and multiple timepoints up to 144 hours after the last dose

  3. The PK of SYHX1901 following single-dose and multiple doses

    The concentration peak time of SYHX1901 following single-dose and multiple doses Concentration peak time The peak time of SYHX1901 concentration following single-dose

    Time frame: Pre-dose and multiple timepoints up to 144 hours after the last dose

  4. The PK of SYHX1901 following single-dose and multiple doses

    The half-time of SYHX1901 following single-dose and multiple doses The half - time of SYHX1901 following single-dose

    Time frame: Pre-dose and multiple timepoints up to 144 hours after the last dose

  5. The PK of SYHX1901 following single-dose and multiple doses

    The plasma clearance rate (CL)of SYHX1901 following single-dose and multiple doses

    Time frame: Pre-dose and multiple timepoints up to 144 hours after the last dose

  6. Urine PK parameters

    Urine pharmacokinetic parameters: The Urine clearance rate (CLr)of SYHX1901

    Time frame: Pre-dose and multiple timepoints up to 144 hours after the dose(180 mg)

  7. Urine PK parameters

    Urine pharmacokinetic parameters: Cumulative excretion from time t1 to t2(Aet1-t2) Fecal pharmacokinetic parameters:Cumulative excretion from time t1 to t2 Urine pharmacokinetic parameters:cumulative excretion from time t1 to t2

    Time frame: Pre-dose and multiple timepoints up to 144 hours after the dose(180 mg)

  8. Fecal PK parameters

    Fecal pharmacokinetic parameters: cumulative excretion from time t1 to t2(Aft1-t2)

    Time frame: Pre-dose and multiple timepoints up to 144 hours after the dose(180 mg)

  9. Identification of Metabolites of SYHX1901

    It is a prospective study aiming to characterize metabolites of 1901 in human plasma, urine and feces. The metabolism profiles of 1901 and main metabolites will be build up.

    Time frame: Pre-dose and multiple timepoints up to 144 hours after the dose(180 mg)

  10. PD indexes: the level of PSTATs in blood cells

    Pharmacodynamic indexes: the level of PSTATs in blood cells

    Time frame: Pre-dose and multiple timepoints up to 144 hours after the last dose

  11. PD indexes: the inhibition rate of PSTATs in blood cells

    Pharmacodynamic indexes: the inhibition rate of PSTATs in blood cells

    Time frame: Pre-dose and multiple timepoints up to 144 hours after the last dose

07

Study locations

1 of 1 sites recruiting
  • Huashan Hospital of Fudan University
    Shanghai, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2021 (actual). Primary completion is estimated for Aug 2022, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2021
First posted
May 10, 2021
StartActual
May 31, 2021
Primary completionEst.
Aug 20, 2022
CompletionEst.
Dec 20, 2022
Last update
Sep 30, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04880512
Responsible party
Sponsor
First posted
May 10, 2021
Start date
May 31, 2021
Primary completion
Aug 20, 2022 (estimated)
Completion
Dec 20, 2022 (estimated)
Last update
Sep 30, 2021

Study contacts

ying hu, master
Contact
hyy1102030@163.com
15021575058
jing zhang, Medical PhD
principal investigator · Huashan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SYHX1901

Start the discussion